Phase 1b/2, Open-Label, Multicenter Study Of ERAS-007 In Combination With Other Anti-Cancer Therapies In Patients With Advanced Non-Small-Cell Lung Cancer (HERKULES-2) Read more
Long-Term, Non-Interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy Read more
A Phase 1/2 Feasibility, Safety, And Activity Study Of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) In Subjects With Previously Treated Advanced Solid Tumors Read more
A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety And Activity Study Of Her-Targeted Dual Switch Car-T Cells (Bpx-603) In Subjects With Previously Treated Advanced Her2-Positive Solid Tumors Read more
Phase 1/2a First-In-Human Study Of BMS-986207 Monoclonal Antibody Alone And In Combination With Nivolumab In Advanced Solid Tumors Read more
Phase 1/2a First-In-Human Study Of BMS-986218 Monoclonal Antibody Alone And In Combination With Nivolumab In Advanced Solid Tumors Read more
A Phase 1/2 First-In-Human Study Of BMS-986249 Alone And In Combination With Nivolumab In Advanced Solid Tumors Read more
A Randomized Phase II/III Open-Label Study Of Ipilimumab And Nivolumab Versus Temozolomide In Patients With Actively Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma Read more
